Table 1.
Antibiotic Susceptibility Pattern of P. aeruginosa at National Reference Laboratory Ethiopia, January 2017 to March 2021
| Antimicrobial Category | Antibiotics | 2017 | 2018 | 2019 | 2020 | 2021 | Total | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N = 26 | N=34 | N=21 | N=12 | N=7 | N=100 | ||||||||||||||
| S | I | R | S | I | R | S | I | R | S | I | R | S | I | R | %S | %I | %R | ||
| Aminoglycosides | Amikacin | 26 | 0 | 0 | 34 | 0 | 0 | 20 | 1 | 0 | 11 | 0 | 1 | 6 | 0 | 1 | 97 | 1 | 2 |
| Gentamicin | 25 | 0 | 1 | 31 | 2 | 1 | 19 | 0 | 2 | 11 | 0 | 1 | 5 | 0 | 2 | 91 | 2 | 7 | |
| Cephalosporins | Cefepime | 21 | 0 | 5 | 25 | 0 | 9 | 12 | 0 | 9 | 7 | 0 | 5 | 4 | 0 | 3 | 69 | 0 | 31 |
| Ceftazidime | 19 | 1 | 6 | 24 | 0 | 10 | 9 | 0 | 12 | 8 | 1 | 3 | 3 | 0 | 4 | 63 | 2 | 35 | |
| Fluoroquinolones | Ciprofloxacin | 23 | 2 | 1 | 29 | 0 | 5 | 12 | 3 | 6 | 9 | 0 | 3 | 4 | 0 | 3 | 77 | 5 | 18 |
| Levofloxacin | 22 | 1 | 3 | 23 | 3 | 8 | 11 | 3 | 7 | 9 | 0 | 3 | 4 | 0 | 3 | 69 | 7 | 24 | |
| Carbapenems | Imipenem | 24 | 2 | 0 | 26 | 2 | 6 | 15 | 0 | 6 | 6 | 2 | 4 | 4 | 1 | 2 | 75 | 7 | 18 |
| Meropenem | 26 | 0 | 0 | 27 | 4 | 3 | 15 | 0 | 6 | 8 | 1 | 3 | 5 | 1 | 1 | 81 | 6 | 13 | |
| Polymyxin B | Colistin | 20 | 4 | 2 | 33 | 0 | 1 | 18 | 0 | 3 | 10 | 2 | 0 | 6 | 1 | 0 | 87 | 7 | 6 |
| β-Lactam combinations | Ceftolozane-tazobactam | 25 | 0 | 1 | 32 | 0 | 2 | 18 | 0 | 3 | 10 | 0 | 2 | 5 | 1 | 1 | 90 | 1 | 9 |
| Piperacillin-tazobactam | 20 | 2 | 4 | 26 | 2 | 6 | 12 | 7 | 2 | 9 | 1 | 2 | 4 | 1 | 2 | 71 | 13 | 16 | |
Abbreviations: S, sensitive; I, intermediate; R, Resistance.